Elypta

Elypta is a Swedish molecular diagnostics company dedicated to reducing cancer mortality through early detection and monitoring. Founded in 2017 as a spinout from Chalmers University of Technology, Elypta is headquartered in Stockholm and focuses on innovative cancer detection technologies.

The company's primary offering is a metabolism-based liquid biopsy platform that measures glycosaminoglycans (GAGome), which serve as biomarkers for tumor metabolism. This platform includes the MIRAM assay kit, a cloud-based software for detecting cancer-specific signatures, and non-invasive blood and urine tests. Elypta's clinical applications target multi-cancer early detection and recurrence detection in renal cell carcinoma, aiming to identify cancers before symptoms arise.

Elypta has successfully raised $32.6 million in funding, positioning itself to capitalize on the growing cancer diagnostics market, projected to reach $28.21 billion by 2029.